Pilze gehörten zu den ersten Quellen für Antibiotika. Die Entdeckung und Entwicklung der β-Lactame vom Penicillin-Typ und Cephalosporin-Typ und ihrer synthetischen Versionen war für die Entstehung der modernen Pharmaindustrie transformativ. Sie bleiben auch 70 Jahre nach ihrer Entdeckung einige der wichtigsten Antibiotika. Inzwischen wurden Tausende von Pilzmetaboliten entdeckt, doch diese Metaboliten haben nur wenige zusätzliche Verbindungen beigetragen, die in die klinische Entwicklung eingetreten sind. In den letzten 15 Jahren nach dem Ausstieg der meisten großen Pharmaunternehmen aus dem Bereich der Entdeckung neuartiger Antibiotika wurden erhebliche Fortschritte bei der Bewertung der biologischen Vielfalt von Pilzen sowie die Verfügbarkeit moderner “-OMICS” -Technologie und revolutionäre Entwicklungen in der Pilzbiotechnologie erzielt.
Daher scheint der Zeitpunkt günstig zu sein, um diese faszinierenden chemisch reichen Organismen als Reservoir niedermolekularer Templates für die Entdeckung von Blei erneut zu betrachten. In dieser Übersicht werden laufende interdisziplinäre Szenarien beschrieben, in denen Spezialisten für Pilzbiologie mit Chemikern, Pharmakologen sowie Biochemie- und Prozessingenieuren zusammenarbeiten, um neue Antibiotika aufzudecken und herzustellen. Die Nützlichkeit eines Vorauswahlprozesses, der auf phylogenetischen Daten und der Verteilung des für den Gencluster kodierenden Sekundärmetaboliten basiert, wird hervorgehoben. Beispiele für neuartige bioaktive Metaboliten von Pilzen, die aus speziellen ökologischen Gruppen stammen, und neue phylogenetische Linien werden ebenfalls diskutiert.
L-Aminosäuren finden in der Biotechnologie verschiedene Anwendungen. L-Glutaminsäure und ihre Salze werden als Geschmacksverstärker verwendet. Andere L-Aminosäuren werden als Lebensmittel- oder Futtermittelzusatzstoffe, in der parenteralen Ernährung oder als Bausteine für die chemische und pharmazeutische Industrie verwendet. L-Aminosäuren werden aus Vorläufern des zentralen Kohlenstoffmetabolismus synthetisiert. Basierend auf der Kenntnis der biochemischen Wege wurden mikrobielle Fermentationsprozesse von Lebensmittel-, Futtermittel- und Pharmaaminosäuren entwickelt. Die Produktionsstämme von Corynebacterium glutamicum, das seit mehr als 50 Jahren in der Lebensmittelbiotechnologie sicher eingesetzt wird, und Escherichia coli werden mithilfe metabolischer Verfahren ständig verbessert. Die Forschung nach neuen Prozessen ist im Gange. Die fermentative Produktion von L-Aminosäuren im Millionen-Tonnen-Maßstab hat die moderne Biotechnologie geprägt und ihre Märkte wachsen stetig weiter. Diese Übersicht konzentriert sich auf die jüngsten Erfolge bei der Stammentwicklung für die Aminosäureproduktion, einschließlich der Verwendung von CRISPRi / dCas9, genomreduzierten Stämmen, Biosensoren und Synthesewegen, um die Nutzung alternativer Kohlenstoffquellen zu ermöglichen.
Pharma-Erfolg in der Produktentwicklung – Verändert die Biotechnologie das Paradigma in der Produktentwicklung und Abnutzung?
Das Biotechnologiesegment der gesamten Biopharmaindustrie besteht seit nur etwa 40 bis 45 Jahren als Treiber für die Entwicklung neuer Produkte. Diese treibende Kraft wurde mit der FDA-Zulassung von rekombinantem Humaninsulin im Jahr 1982 initiiert, das von der Firma Genentech stammt. Die Pharmaindustrie beschäftigte sich in den frühen Jahren der 1970er und 1980er Jahre nur in geringem Maße mit Biotechnologieunternehmen, indem sie einige rekombinante Moleküle unter der Leitung von Roche, Eli Lilly sowie Johnson und Johnson einlizenzierte. Später und dramatisch in den letzten 25 Jahren hat sich die Biotechnologie jedoch zu einem Haupttreiber für Produkt- und Technologieinnovationen entwickelt und ist zu einem Eckpfeiler bei der Entwicklung neuer Produkte durch alle Biopharma-Unternehmen geworden.
Diese Überprüfung zeigt diese evolutionären Änderungen in Bezug auf zugelassene Produkte, Produktpipelines, Neuheit der Produkte, FDA-Zulassungsraten, Produktverkäufe, finanzielle F & E-Investitionen in Biotechnologie, Partnerschaften, Fusionen und Übernahmen sowie Patentfragen. Wir haben jetzt ungefähr 300 in den USA zugelassene Biotechnologieprodukte für 16 medizinische Disziplinen und ungefähr 250 Indikationen, an denen 25 Pharmaunternehmen sowie deren Innovatoren und Partner aus dem Biotechnologieunternehmen beteiligt sind. Die Biotechnologie-Pipeline umfasst über 1000 Moleküle in klinischen Studien, darunter über 300 Moleküle, die mit den Top-10-Pharmaunternehmen verbunden sind. Die Produktzulassungsraten der FDA für Biotechnologieprodukte sind mehr als doppelt so hoch wie für Arzneimittel. Ja, das F & E-Paradigma hat sich mit der Biotechnologie geändert, da einer der Hauptschwerpunkte für die Entwicklung neuer Produkte mit neuartigen Molekülen der gesamten Biopharmaindustrie ist.

Relevanz der Grenzflächenviskoelastizität für die Stabilität und Konformation biomolekularer Organe an der Luft / Flüssigkeits-Grenzfläche.
Weiche Materialien sind komplexe makromolekulare Systeme, die häufig verwirrende nicht-Newtonsche viskoelastische Eigenschaften aufweisen, insbesondere wenn die Makromoleküle verwickelt, überfüllt oder vernetzt sind. Diese Materialien sind in der Biologie, Lebensmittel- und Pharmaindustrie allgegenwärtig und finden verschiedene Anwendungen in der Biotechnologie und auf dem Gebiet der Biosensoren. Basierend auf den Längenskalen, Topologien, Flexibilität und Konzentration verhalten sich die Systeme sowohl als Flüssigkeiten (viskos) als auch als Feststoffe (elastisch).
Insbesondere für Proteine und Protein-Lipid-Systeme ist die Viskoelastizität ein wichtiger Parameter, da sie häufig direkt mit der Stabilität und den thermodynamischen Wechselwirkungen der reinen biologischen Komponenten sowie ihrer Gemische zusammenhängt. Trotz der umfangreichen Arbeit, die in der Lösungsmakrorheometrie verfügbar ist, gibt es immer noch eine Reihe von Problemen, die beim Umgang mit Proteinen an Luft / Flüssigkeits-Grenzflächen und mit Protein-Polymer- oder Protein-Lipid-Grenzflächen, die häufig sehr stark sind, angegangen werden müssen niedrige Grenzflächenviskositätswerte. In Anbetracht der wichtigen Anwendungen, die sie in der biopharmazeutischen, biotechnologischen und nutrazeutischen Industrie haben, besteht ein Bedarf an der Entwicklung von Methoden, die die folgenden drei spezifischen Probleme erfüllen: kleines Volumen, großer dynamischer Bereich der Schergeschwindigkeiten und Grenzflächeneigenschaften verschiedener Biomoleküle. Ferner sollten die Techniken, die entwickelt werden, Newtonsche, Scherverdünnungs- und Ausbeuteeigenschaften umfassen, die repräsentativ für das unterschiedliche Lösungsverhalten sind, das typischerweise auftritt.
Desmin antibody |
70R-3807 |
Fitzgerald |
50 ug |
EUR 560.4 |
Description: Rabbit polyclonal Desmin antibody raised against the middle region of DES |
Desmin antibody |
70R-49656 |
Fitzgerald |
100 ul |
EUR 292.8 |
Description: Purified Polyclonal Desmin antibody |
Desmin antibody |
70R-36046 |
Fitzgerald |
100 ug |
EUR 392.4 |
Description: Rabbit polyclonal Desmin antibody |
Desmin antibody |
70R-31159 |
Fitzgerald |
100 ug |
EUR 392.4 |
Description: Rabbit polyclonal Desmin antibody |
Desmin Antibody |
48577-100ul |
SAB |
100ul |
EUR 399.6 |
Desmin Antibody |
48577-50ul |
SAB |
50ul |
EUR 286.8 |
Desmin Antibody |
48749-100ul |
SAB |
100ul |
EUR 399.6 |
Desmin Antibody |
48749-50ul |
SAB |
50ul |
EUR 286.8 |
Desmin Peptide |
46-777P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: Desmin Peptide |
Desmin antibody |
70R-10682 |
Fitzgerald |
1 ml |
EUR 447.6 |
Description: Rabbit polyclonal Desmin antibody |
Desmin antibody |
70R-1238 |
Fitzgerald |
100 ug |
EUR 452.4 |
Description: Rabbit polyclonal Desmin antibody raised against the N terminal of DES |
Desmin protein |
30R-2118 |
Fitzgerald |
250 ug |
EUR 864 |
Description: Purified recombinant Human Desmin protein |
Desmin protein |
30R-2129 |
Fitzgerald |
100 ug |
EUR 391.2 |
Description: Purified native Chicken Desmin Protein |
Desmin protein |
30R-2138 |
Fitzgerald |
100 ug |
EUR 558 |
Description: Purified recombinant Human Desmin protein |
Desmin antibody |
20R-DR029 |
Fitzgerald |
500 ul |
EUR 716.4 |
Description: Rabbit polyclonal Desmin antibody |
Desmin antibody |
10R-7851 |
Fitzgerald |
100 ug |
EUR 386.4 |
Description: Mouse monoclonal Desmin antibody |
Desmin antibody |
10R-7985 |
Fitzgerald |
100 ug |
EUR 495.6 |
Description: Mouse monoclonal Desmin antibody |
Desmin antibody |
10R-7986 |
Fitzgerald |
100 ug |
EUR 502.8 |
Description: Mouse monoclonal Desmin antibody |
Desmin antibody |
10R-2030 |
Fitzgerald |
100 ul |
EUR 418.8 |
Description: Mouse monoclonal Desmin antibody |
Desmin antibody |
10R-D101a |
Fitzgerald |
1 mL |
EUR 657.6 |
Description: Mouse monoclonal Desmin antibody |
Desmin Antibody |
33355-100ul |
SAB |
100ul |
EUR 302.4 |
Desmin Antibody |
33355-50ul |
SAB |
50ul |
EUR 224.4 |
Desmin Protein |
20-abx261990 |
Abbexa |
-
EUR 5388.00
-
EUR 393.60
-
EUR 276.00
|
|
|
Desmin protein |
E20-80025 |
EnoGene |
20ug |
EUR 489.6 |
Desmin Antibody |
V9390-100UG |
NSJ Bioreagents |
100ug |
EUR 499 |
Description: Cytoskeletal intermediate filaments (IFs) constitute a diverse group of proteins that are expressed in a highly tissue-specific manner. IFs are constructed from two-chain -helical coiled-coil molecules arranged on an imperfect helical lattice, and have been widely used as markers for distinguishing individual cell types within a tissue and identifying the origins of metastatic tumors. Vimentin is an IF general marker of cells originating in the mesenchyme. Vimentin and Desmin, a related class III IF, are both expressed during skeletal muscle development. Desmin, a 469 amino acid protein found near the Z line in sarcomeres, is expressed more frequently in adult differentiated state tissues. Anti-desmin detects cells of normal smooth, skeletal, and cardiac muscles.Antibody reacts with leiomyomas, leiomyosarcoma, rhabdomyomas, rhabdomyosarcoma, and perivascular cells of glomus tumors of the skin. |
Desmin Antibody |
V9390-20UG |
NSJ Bioreagents |
20ug |
EUR 219 |
Description: Cytoskeletal intermediate filaments (IFs) constitute a diverse group of proteins that are expressed in a highly tissue-specific manner. IFs are constructed from two-chain -helical coiled-coil molecules arranged on an imperfect helical lattice, and have been widely used as markers for distinguishing individual cell types within a tissue and identifying the origins of metastatic tumors. Vimentin is an IF general marker of cells originating in the mesenchyme. Vimentin and Desmin, a related class III IF, are both expressed during skeletal muscle development. Desmin, a 469 amino acid protein found near the Z line in sarcomeres, is expressed more frequently in adult differentiated state tissues. Anti-desmin detects cells of normal smooth, skeletal, and cardiac muscles.Antibody reacts with leiomyomas, leiomyosarcoma, rhabdomyomas, rhabdomyosarcoma, and perivascular cells of glomus tumors of the skin. |
Desmin Antibody |
V9390SAF-100UG |
NSJ Bioreagents |
100ug |
EUR 499 |
Description: Cytoskeletal intermediate filaments (IFs) constitute a diverse group of proteins that are expressed in a highly tissue-specific manner. IFs are constructed from two-chain -helical coiled-coil molecules arranged on an imperfect helical lattice, and have been widely used as markers for distinguishing individual cell types within a tissue and identifying the origins of metastatic tumors. Vimentin is an IF general marker of cells originating in the mesenchyme. Vimentin and Desmin, a related class III IF, are both expressed during skeletal muscle development. Desmin, a 469 amino acid protein found near the Z line in sarcomeres, is expressed more frequently in adult differentiated state tissues. Anti-desmin detects cells of normal smooth, skeletal, and cardiac muscles.Antibody reacts with leiomyomas, leiomyosarcoma, rhabdomyomas, rhabdomyosarcoma, and perivascular cells of glomus tumors of the skin. |
Desmin Antibody |
V9768-100UG |
NSJ Bioreagents |
100ug |
EUR 499 |
Description: Cytoskeletal intermediate filaments (IFs) constitute a diverse group of proteins that are expressed in a highly tissue-specific manner. IFs are constructed from two-chain α-helical coiled-coil molecules arranged on an imperfect helical lattice, and have been widely used as markers for distinguishing individual cell types within a tissue and identifying the origins of metastatic tumors. Vimentin is an IF general marker of cells originating in the mesenchyme. Vimentin and Desmin, a related class III IF, are both expressed during skeletal muscle development. Desmin, a 469 amino acid protein found near the Z line in sarcomeres, is expressed more frequently in adult differentiated state tissues. Anti-desmin detects cells of normal smooth, skeletal, and cardiac muscles. Antibody reacts with leiomyomas, leiomyosarcoma, rhabdomyomas, rhabdomyosarcoma, and perivascular cells of glomus tumors of the skin. |
Desmin Antibody |
V9768-20UG |
NSJ Bioreagents |
20ug |
EUR 219 |
Description: Cytoskeletal intermediate filaments (IFs) constitute a diverse group of proteins that are expressed in a highly tissue-specific manner. IFs are constructed from two-chain α-helical coiled-coil molecules arranged on an imperfect helical lattice, and have been widely used as markers for distinguishing individual cell types within a tissue and identifying the origins of metastatic tumors. Vimentin is an IF general marker of cells originating in the mesenchyme. Vimentin and Desmin, a related class III IF, are both expressed during skeletal muscle development. Desmin, a 469 amino acid protein found near the Z line in sarcomeres, is expressed more frequently in adult differentiated state tissues. Anti-desmin detects cells of normal smooth, skeletal, and cardiac muscles. Antibody reacts with leiomyomas, leiomyosarcoma, rhabdomyomas, rhabdomyosarcoma, and perivascular cells of glomus tumors of the skin. |
Desmin Antibody |
V9768SAF-100UG |
NSJ Bioreagents |
100ug |
EUR 499 |
Description: Cytoskeletal intermediate filaments (IFs) constitute a diverse group of proteins that are expressed in a highly tissue-specific manner. IFs are constructed from two-chain α-helical coiled-coil molecules arranged on an imperfect helical lattice, and have been widely used as markers for distinguishing individual cell types within a tissue and identifying the origins of metastatic tumors. Vimentin is an IF general marker of cells originating in the mesenchyme. Vimentin and Desmin, a related class III IF, are both expressed during skeletal muscle development. Desmin, a 469 amino acid protein found near the Z line in sarcomeres, is expressed more frequently in adult differentiated state tissues. Anti-desmin detects cells of normal smooth, skeletal, and cardiac muscles. Antibody reacts with leiomyomas, leiomyosarcoma, rhabdomyomas, rhabdomyosarcoma, and perivascular cells of glomus tumors of the skin. |
Desmin Antibody |
V3200-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Cytoskeletal intermediate filaments (IFs) constitute a diverse group of proteins that are expressed in a highly tissue-specific manner. IFs are constructed from two-chain α-helical coiled-coil molecules arranged on an imperfect helical lattice, and have been widely used as markers for distinguishing individual cell types within a tissue and identifying the origins of metastatic tumors. Vimentin is an IF general marker of cells originating in the mesenchyme. Vimentin and Desmin, a related class III IF, are both expressed during skeletal muscle development. Desmin, a 469 amino acid protein found near the Z line in sarcomeres, is expressed more frequently in adult differentiated state tissues. Anti-desmin detects cells of normal smooth, skeletal, and cardiac muscles. Antibody reacts with leiomyomas, leiomyosarcoma, rhabdomyomas, rhabdomyosarcoma, and perivascular cells of glomus tumors of the skin. |
Desmin Antibody |
V3200-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: Cytoskeletal intermediate filaments (IFs) constitute a diverse group of proteins that are expressed in a highly tissue-specific manner. IFs are constructed from two-chain α-helical coiled-coil molecules arranged on an imperfect helical lattice, and have been widely used as markers for distinguishing individual cell types within a tissue and identifying the origins of metastatic tumors. Vimentin is an IF general marker of cells originating in the mesenchyme. Vimentin and Desmin, a related class III IF, are both expressed during skeletal muscle development. Desmin, a 469 amino acid protein found near the Z line in sarcomeres, is expressed more frequently in adult differentiated state tissues. Anti-desmin detects cells of normal smooth, skeletal, and cardiac muscles. Antibody reacts with leiomyomas, leiomyosarcoma, rhabdomyomas, rhabdomyosarcoma, and perivascular cells of glomus tumors of the skin. |
Desmin Antibody |
V3200SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Cytoskeletal intermediate filaments (IFs) constitute a diverse group of proteins that are expressed in a highly tissue-specific manner. IFs are constructed from two-chain α-helical coiled-coil molecules arranged on an imperfect helical lattice, and have been widely used as markers for distinguishing individual cell types within a tissue and identifying the origins of metastatic tumors. Vimentin is an IF general marker of cells originating in the mesenchyme. Vimentin and Desmin, a related class III IF, are both expressed during skeletal muscle development. Desmin, a 469 amino acid protein found near the Z line in sarcomeres, is expressed more frequently in adult differentiated state tissues. Anti-desmin detects cells of normal smooth, skeletal, and cardiac muscles. Antibody reacts with leiomyomas, leiomyosarcoma, rhabdomyomas, rhabdomyosarcoma, and perivascular cells of glomus tumors of the skin. |
Standard |
abx098954-10vials |
Abbexa |
10 vials |
EUR 2614.8 |
|
Standard |
abx098954-1vial |
Abbexa |
1 vial |
EUR 360 |
|
Standard |
abx098954-5vials |
Abbexa |
5 vials |
EUR 1412.4 |
|
Standard |
abx098955-10vials |
Abbexa |
10 vials |
EUR 2614.8 |
|
Standard |
abx098955-1vial |
Abbexa |
1 vial |
EUR 360 |
|
Standard |
abx098955-5vials |
Abbexa |
5 vials |
EUR 1412.4 |
|
Standard |
abx098956-10vials |
Abbexa |
10 vials |
EUR 2614.8 |
|
Standard |
abx098956-1vial |
Abbexa |
1 vial |
EUR 360 |
|
Standard |
abx098956-5vials |
Abbexa |
5 vials |
EUR 1412.4 |
|
Standard |
abx098963-10vials |
Abbexa |
10 vials |
EUR 2614.8 |
|
Standard |
abx098963-1vial |
Abbexa |
1 vial |
EUR 360 |
|
Standard |
abx098963-5vials |
Abbexa |
5 vials |
EUR 1412.4 |
|
Standard |
abx098965-10vials |
Abbexa |
10 vials |
EUR 2614.8 |
|
Standard |
abx098965-1vial |
Abbexa |
1 vial |
EUR 360 |
|
Standard |
abx098965-5vials |
Abbexa |
5 vials |
EUR 1412.4 |
|
Standard |
abx098967-10vials |
Abbexa |
10 vials |
EUR 2614.8 |
|
Standard |
abx098967-1vial |
Abbexa |
1 vial |
EUR 360 |
|
Standard |
abx098967-5vials |
Abbexa |
5 vials |
EUR 1412.4 |
|
Standard |
abx098968-10vials |
Abbexa |
10 vials |
EUR 2614.8 |
|
Standard |
abx098968-1vial |
Abbexa |
1 vial |
EUR 360 |
|
Standard |
abx098968-5vials |
Abbexa |
5 vials |
EUR 1412.4 |
|
Standard |
abx098969-10vials |
Abbexa |
10 vials |
EUR 2614.8 |
|
Standard |
abx098969-1vial |
Abbexa |
1 vial |
EUR 360 |
|
Standard |
abx098969-5vials |
Abbexa |
5 vials |
EUR 1412.4 |
|
Standard |
abx092106-1vial |
Abbexa |
1 vial |
EUR 260.4 |
|
Standard |
abx296006-1vial |
Abbexa |
1 vial |
EUR 360 |
|
Desmin Polyclonal Antibody |
ABP51163-003ml |
Abbkine |
0.03ml |
EUR 189.6 |
|
Description: A polyclonal antibody for detection of Desmin from Human, Mouse, Rat. This Desmin antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Desmin at AA range: 390-470 |
Desmin Polyclonal Antibody |
ABP51163-01ml |
Abbkine |
0.1ml |
EUR 346.8 |
|
Description: A polyclonal antibody for detection of Desmin from Human, Mouse, Rat. This Desmin antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Desmin at AA range: 390-470 |
Desmin Polyclonal Antibody |
ABP51163-02ml |
Abbkine |
0.2ml |
EUR 496.8 |
|
Description: A polyclonal antibody for detection of Desmin from Human, Mouse, Rat. This Desmin antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Desmin at AA range: 390-470 |
Desmin Polyclonal Antibody |
ABP51164-003ml |
Abbkine |
0.03ml |
EUR 189.6 |
|
Description: A polyclonal antibody for detection of Desmin from Human, Mouse, Rat. This Desmin antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Desmin around the non-phosphorylation site of S60 |
Desmin Polyclonal Antibody |
ABP51164-01ml |
Abbkine |
0.1ml |
EUR 346.8 |
|
Description: A polyclonal antibody for detection of Desmin from Human, Mouse, Rat. This Desmin antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Desmin around the non-phosphorylation site of S60 |
Desmin Polyclonal Antibody |
ABP51164-02ml |
Abbkine |
0.2ml |
EUR 496.8 |
|
Description: A polyclonal antibody for detection of Desmin from Human, Mouse, Rat. This Desmin antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Desmin around the non-phosphorylation site of S60 |
Desmin Conjugated Antibody |
C33355 |
SAB |
100ul |
EUR 476.4 |
Desmin Blocking Peptide |
AF5334-BP |
Affbiotech |
1mg |
EUR 234 |
Desmin Blocking Peptide |
AF0147-BP |
Affbiotech |
1mg |
EUR 234 |
anti- Desmin antibody |
FNab02340 |
FN Test |
100µg |
EUR 606.3 |
|
Description: Antibody raised against Desmin |
anti- Desmin antibody |
FNab02341 |
FN Test |
100µg |
EUR 658.5 |
|
Description: Antibody raised against Desmin |
anti- Desmin antibody |
FNab02342 |
FN Test |
100µg |
EUR 658.5 |
|
Description: Antibody raised against Desmin |
Desmin Monoclonal Antibody |
EM1218-100ul |
ELK Biotech |
100ul |
EUR 334.8 |
Description: A Mouse Monoclonal antibody against Desmin from Human/ Rat/ Mouse. This antibody is tested and validated for IHC |
Desmin Monoclonal Antibody |
EM1218-50ul |
ELK Biotech |
50ul |
EUR 248.4 |
Description: A Mouse Monoclonal antibody against Desmin from Human/ Rat/ Mouse. This antibody is tested and validated for IHC |
Desmin Polyclonal Antibody |
ES2162-100ul |
ELK Biotech |
100ul |
EUR 334.8 |
Description: A Rabbit Polyclonal antibody against Desmin from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA |
Desmin Polyclonal Antibody |
ES2162-50ul |
ELK Biotech |
50ul |
EUR 248.4 |
Description: A Rabbit Polyclonal antibody against Desmin from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA |
Desmin Polyclonal Antibody |
ES2163-100ul |
ELK Biotech |
100ul |
EUR 334.8 |
Description: A Rabbit Polyclonal antibody against Desmin from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA |
Desmin Polyclonal Antibody |
ES2163-50ul |
ELK Biotech |
50ul |
EUR 248.4 |
Description: A Rabbit Polyclonal antibody against Desmin from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA |
Desmin antibody (Ser60) |
70R-35266 |
Fitzgerald |
100 ug |
EUR 392.4 |
Description: Purified Rabbit polyclonal Desmin antibody (Ser60) |
Desmin Recombinant Protein |
92-030 |
ProSci |
0.05 mg |
EUR 821.4 |
Description: Desmin is a cytoplasmic protein and belongs to the intermediate filament family. interacts with DST and MTM1. Desmin is only expressed in vertebrates, however homologous proteins are found in many organisms. Desmin is the main intermediate filament in mature skeletal, cardiac and smooth-muscle cells. DES founctions as homopolymers to form a stable intracytoplasmic filamentous network connecting myofibrils to each other and to the plasma membrane. .Defects in DES are cause of the myopathy myofibrillar type 1, cardiomyopathy dilated type 1I, and neurogenic scapuloperoneal syndrome Kaeser type. |
Desmin protein (Chicken) |
30R-AD003 |
Fitzgerald |
250 ug |
EUR 657.6 |
Description: Purified native Chicken Desmin protein |
Desmin Polyclonal Antibody |
40839-100ul |
SAB |
100ul |
EUR 302.4 |
Desmin Polyclonal Antibody |
40839-50ul |
SAB |
50ul |
EUR 224.4 |
Desmin Blocking Peptide |
33R-5684 |
Fitzgerald |
100 ug |
EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DES antibody, catalog no. 70R-3807 |
Desmin Blocking Peptide |
33R-7209 |
Fitzgerald |
100 ug |
EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of DES antibody, catalog no. 70R-1238 |
Desmin (Des) Antibody |
20-abx100036 |
Abbexa |
-
EUR 477.60
-
EUR 159.60
-
EUR 1328.40
-
EUR 644.40
-
EUR 376.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Desmin (DES) Antibody |
20-abx159470 |
Abbexa |
|
|
|
Desmin (Des) Antibody |
20-abx172093 |
Abbexa |
|
|
|
Desmin (Des) Antibody |
20-abx172094 |
Abbexa |
|
|
|
Desmin (DES) Antibody |
abx122581-100ug |
Abbexa |
100 ug |
EUR 469.2 |
|
Desmin (DES) Antibody |
20-abx125113 |
Abbexa |
-
EUR 710.40
-
EUR 1028.40
-
EUR 260.40
-
EUR 493.20
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
Desmin (DES) Antibody |
20-abx125323 |
Abbexa |
-
EUR 594.00
-
EUR 844.80
-
EUR 427.20
|
|
|
Desmin (DES) Antibody |
20-abx112046 |
Abbexa |
|
|
|
Desmin (DES) Antibody |
20-abx000692 |
Abbexa |
|
|
|
Desmin (DES) Antibody |
20-abx000834 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
Desmin (DES) Antibody |
abx020549-100ug |
Abbexa |
100 ug |
EUR 560.4 |
|
Desmin (DES) Antibody |
abx010636-100ul |
Abbexa |
100 ul |
EUR 493.2 |
|
Desmin (DES) Antibody |
20-abx013058 |
Abbexa |
-
EUR 376.80
-
EUR 117.60
-
EUR 477.60
-
EUR 594.00
|
- 100 ug
- 10 ug
- 200 ug
- 300 µg
|
|
Desmin (DES) Antibody |
20-abx009339 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
Desmin Blocking Peptide |
20-abx062531 |
Abbexa |
|
|
|
Desmin (DES) Antibody |
abx027938-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
Desmin (DES) Antibody |
abx027938-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
Desmin (DES) Antibody |
abx031687-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
Desmin (DES) Antibody |
abx031687-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
Desmin (DESM) Antibody |
abx025293-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
Desmin (DESM) Antibody |
abx025293-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
Anti-Desmin Antibody |
A2001-100 |
Biovision |
100 µl |
EUR 405.6 |
Desmin Monoclonal Antibody |
ABM40221-003ml |
Abbkine |
0.03ml |
EUR 189.6 |
|
Description: A monoclonal antibody for detection of Desmin from Human, Mouse, Rat. This Desmin antibody is for IHC-P, IF. It is affinity-purified from mouse ascites by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in mouse by using as an immunogen recombinant protein |
Desmin Monoclonal Antibody |
ABM40221-01ml |
Abbkine |
0.1ml |
EUR 346.8 |
|
Description: A monoclonal antibody for detection of Desmin from Human, Mouse, Rat. This Desmin antibody is for IHC-P, IF. It is affinity-purified from mouse ascites by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in mouse by using as an immunogen recombinant protein |
Desmin Monoclonal Antibody |
ABM40221-02ml |
Abbkine |
0.2ml |
EUR 496.8 |
|
Description: A monoclonal antibody for detection of Desmin from Human, Mouse, Rat. This Desmin antibody is for IHC-P, IF. It is affinity-purified from mouse ascites by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in mouse by using as an immunogen recombinant protein |
Desmin Rabbit mAb |
A3736 |
Abclonal |
20 μL |
EUR 18 |
Desmin Rabbit mAb |
A3736-100ul |
Abclonal |
100 ul |
EUR 492 |
Desmin Rabbit mAb |
A3736-200ul |
Abclonal |
200 ul |
EUR 685.2 |
Desmin Rabbit mAb |
A3736-20ul |
Abclonal |
20 ul |
EUR 265.2 |
Desmin Rabbit mAb |
A3736-50ul |
Abclonal |
50 ul |
EUR 344.4 |
Desmin (DES) Antibody |
abx232340-100ug |
Abbexa |
100 ug |
EUR 577.2 |
|
Desmin (DES) Antibody |
abx232341-100ug |
Abbexa |
100 ug |
EUR 610.8 |
|
Desmin (DES) Antibody |
abx232342-100ug |
Abbexa |
100 ug |
EUR 610.8 |
|
Desmin (DES) Antibody |
20-abx329232 |
Abbexa |
|
|
|
Desmin (DES) Antibody |
abx431203-200ul |
Abbexa |
200 ul |
EUR 460.8 |
|
Desmin (DES) Antibody |
20-abx302193 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Die hier vorgestellte Übersicht ist eine umfassende Darstellung der rheologischen Eigenschaften verschiedener Biomoleküle an den Grenzflächen Luft / Flüssigkeit und Feststoff / Flüssigkeit. Es befasst sich mit der Nützlichkeit der “Viskoelastizität” der Systeme an den auf molekularer Ebene analysierten Grenzflächen, die mit den mikroskopischen Materialeigenschaften korreliert werden können, und geht auf einige neuere Techniken in der Mikrorheologie ein, mit denen die ungewöhnlich niedrigen Viskositätswerte empfindlich gemessen werden.